On Wednesday, Dr Reddy's Laboratories Ltd reported a 76 percent year-on-year (YoY) jump in the company's net profit for the quarter ended 31 March 2020 at Rs 764.2 crore against Rs 434.4 crore in the same period of the previous year.
The company's EBITDA (earnings before interest, taxes, depreciation, and amortization) came at Rs 1,001 crore and EBITDA margin for the quarter was 22.6 percent.
The company's global generics segment clocked a 20 percent year-on-year jump in revenue to Rs 3,639.8 crore.
Among the geographies, its Europe's segment saw 80 percent surge in revenue from the previous year, while North America, Emerging Markets and India rose 21 percent, 15 percent and 5 percent, respectively YoY.
Dr Reddy's Laboratories Ltd's board has recommended a final dividend of Rs 25 (500 percent) per equity share of Rs 5 face value for the financial year 2019-20. It will be paid on or after 5 days from the date of declaration of the final dividend by the shareholders at the 36th Annual General Meeting (AGM), the company said, adding that in view of the COVID-19 situation, it is working on an AGM date.
The company also said that it has taken various initiatives to ensure that its manufacturing-related operations continue unabated amid the COVID-19 related disruptions. A few products related to COVID-19 are also under development.